Vaxcyte, Inc. (PCVX) – What Are Researchers Saying About This Stock?

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $110.50.

Several research firms have recently issued reports on PCVX. BTIG Research reiterated a “buy” rating and set a $89.00 target price on shares of Vaxcyte in a report on Monday, October 5th. Bank of America dropped their price target on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research note on Monday, September 28th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Needham & Company LLC increased their price objective on Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Finally, Guggenheim lifted their target price on shares of Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, October 5th.

Insiders Place Their Bets

In other news, EVP Jim Wassil sold 18,000 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $86.74, for a total value of $1,561,320.00. Following the completion of the sale, the executive vice president directly owned 145,435 shares in the company, valued at $12,615,031.90. This represents a 11.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the completion of the transaction, the chief financial officer directly owned 105,176 shares in the company, valued at approximately $5,667,934.64. This represents a 8.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 92,890 shares of company stock valued at $6,320,569. 3.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jupiter Topco LLC bought a new stake in Vaxcyte during the 2nd quarter valued at about $1,044,355,000. BlackRock Inc. purchased a new position in shares of Vaxcyte during the second quarter valued at $701,520,000. Janus Henderson Group PLC grew its holdings in Vaxcyte by 23.8% during the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after acquiring an additional 3,188,687 shares in the last quarter. Wellington Management Group LLP grew its holdings in Vaxcyte by 24.7% during the 2nd quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company’s stock worth $407,001,000 after acquiring an additional 1,386,968 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Vaxcyte in the 2nd quarter worth approximately $62,711,000. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Stock Performance

PCVX opened at $60.43 on Friday. The stock’s 50 day moving average price is $61.59 and its 200-day moving average price is $57.28. Vaxcyte has a 52-week low of $39.87 and a 52-week high of $90.75. The stock has a market capitalization of $8.99 billion, a PE ratio of -7.92 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same quarter in the prior year, the business earned ($1.22) earnings per share. Research analysts forecast that Vaxcyte will post -7.47 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.